药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Tasosartan
Varicella Zoster Vaccine (Recombinant)
The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Palbociclib.
Tasosartan
Yersinia pestis 195/p antigen (formaldehyde inactivated)
The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Palbociclib.
Tasosartan
Pertussis vaccine
The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Palbociclib.
Tasosartan
Smallpox (Vaccinia) Vaccine, Live
The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Palbociclib.
Tasosartan
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Palbociclib.
Tasosartan
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Palbociclib.
Tasosartan
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Palbociclib.
Tasosartan
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Palbociclib.
Tasosartan
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Palbociclib.
Tasosartan
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Palbociclib.
Tasosartan
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Palbociclib.
Tasosartan
Typhoid vaccine
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Palbociclib.
Tasosartan
Tecemotide
The therapeutic efficacy of Tecemotide can be decreased when used in combination with Palbociclib.
Tasosartan
Hepatitis B Vaccine (Recombinant)
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Palbociclib.
Tasosartan
Human rabies virus immune globulin
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Palbociclib.
Tasosartan
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Palbociclib.
Tasosartan
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Palbociclib.
Tasosartan
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Palbociclib.
Tasosartan
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Palbociclib.
Tasosartan
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Palbociclib.